Consumer medicine information

Zofran Zydis Wafers

Ondansetron

BRAND INFORMATION

Brand name

Zofran

Active ingredient

Ondansetron

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Zofran Zydis Wafers.

What is in this leaflet

Please read this leaflet carefully before you start taking Zofran Zydis wafers.

This leaflet answers some common questions about Zofran Zydis wafers. It does not contain all of the available information.

It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Zofran Zydis wafers against the benefits this medicine is expected to have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What Zofran Zydis wafers are used for

Zofran Zydis wafers belong to a group of medicines called antiemetics.

Zofran Zydis wafers work by helping to stop the nausea (sick feeling) and vomiting which can occur after certain treatments. 'Wafer' used in the product name, is the word used for the special type of tablet which dissolves in a few seconds when placed on the tongue. It is easier to swallow than ordinary tablets.

Zofran Zydis wafers should only be used to treat the nausea and vomiting for which they have been prescribed.

Your doctor may have prescribed Zofran Zydis wafers for another reason.

Ask your doctor if you have any questions about why Zofran Zydis wafers have been prescribed for you.

Zofran Zydis wafers are not addictive.

Before you take Zofran Zydis wafers

When you must not take them

  • Do not take Zofran Zydis wafers if you are taking apomorphine (used to treat Parkinson's disease).
  • Do not take Zofran Zydis wafers if you have ever had an allergic reaction to ondansetron or any of the ingredients listed at the end of this leaflet.
    Symptoms of an allergic reaction may be mild or severe. They usually include some or all of the following: wheezing, swelling of the lips/mouth, difficulty in breathing, hayfever, lumpy rash ("hives") or fainting.
  • Do not take Zofran Zydis wafers if you are pregnant, trying to become pregnant or breastfeeding, unless your doctor says you should.
    Your doctor will discuss the risks and benefits of using Zofran Zydis wafers if you are pregnant or breastfeeding.
  • Do not take Zofran Zydis wafers after the expiry date (EXP) printed on the pack.
    If you take it after the expiry date has passed, it may not work as well.
  • Do not take Zofran Zydis wafers if the packaging is torn or shows signs of tampering.

If you're not sure whether you should be taking Zofran Zydis wafers, talk to your doctor.

Before you start to take them

You must tell your doctor if:

  • you are allergic to foods, dyes, preservatives or any other medicines.
  • you have, or used to have, liver problems.
  • you suffer from severe constipation or have a blockage in your gut.
  • you have phenylketonuria, as Zofran Zydis wafers contain aspartame.

Taking other medicines

Tell your doctor if you are taking any other medicines, including medicines you buy without a prescription from a pharmacy, supermarket or health food shop.

Some medicines may affect the way others work. Your doctor or pharmacist will be able to tell you what to do when taking Zofran Zydis wafers with other medicines.

Use in children

There is limited experience in children. Zofran Zydis wafers can be taken by children over 4 years of age.

How to take Zofran Zydis wafers

The pharmacist's label on the pack will tell you how to take Zofran Zydis wafers. If there is something you do not understand, ask your doctor or pharmacist.

How much to take

DO NOT take more Zofran Zydis wafers than your doctor or pharmacist tells you.

DO NOT take Zofran Zydis wafers MORE OFTEN than your doctor or pharmacist tells you.

If you vomit within one hour of taking your first Zofran Zydis wafer of each course prescribed for you, you should take the same dose again. If you continue to vomit, tell your doctor.

How to take them

PEEL BACK the foil top of the blister strip and GENTLY remove the Zofran Zydis wafer. (DO NOT try to push it through the foil top as the wafer is fragile and will break up inside the foil). Place the Zofran Zydis wafer on top of your tongue. It will disappear very quickly, then swallow as normal.

When to take them

Your doctor or pharmacist will be able to tell you when you should take your Zofran Zydis wafers.

How long to take them

Your doctor or pharmacist will be able to tell you how long you should take your Zofran Zydis wafers.

If you forget to take them

If you miss your dose and you do not feel sick take your next dose when you are meant to.

If you miss your dose, and you feel sick, take the missed dose as soon as possible, then go back to taking your Zofran Zydis wafer as you would normally. If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

If you take too much (overdose)

Immediately telephone your doctor or Poisons Information Centre (telephone 13 11 26) for advice, if you think you or anyone else may have taken too much Zofran Zydis wafers, even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

Keep telephone numbers for these places handy.

If you are not sure what to do, contact your doctor or pharmacist.

While you are taking Zofran Zydis wafers

Things you must do

Tell your doctor or pharmacist that you are taking Zofran Zydis wafers if you are about to be started on any new medicines.

Tell your doctor if you become pregnant or are trying to become pregnant.

Tell your doctor if, for any reason, you have not taken your medicine exactly as prescribed. Otherwise, your doctor may think that it was not effective and change your treatment unnecessarily.

Things you must not do

Do not stop taking Zofran Zydis wafers, or change the dose without first checking with your doctor.

Do not give this medicine to anyone else, even if their symptoms seem similar to yours.

Do not use Zofran Zydis wafers to treat any other complaints unless your doctor says to.

Side effects

Check with your doctor as soon as possible if you have any problems while taking Zofran Zydis wafers, even if you do not think the problems are connected with the medicine or are not listed in this leaflet. Like other medicines, Zofran Zydis wafers can cause some side effects. If they occur, they are most likely to be minor and temporary. However, some may be serious and need medical attention.

The most commonly reported side effects are:

  • headache
  • a sensation of warmth or flushing
  • mild stomach cramps
  • constipation or diarrhoea
  • dry mouth
  • hiccups
  • dizziness or light-headed feeling.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist immediately if you notice any of the following:

  • chest pain or tightness of chest
  • changes in the way your heart beats eg if you notice it beating faster or slower than normal, or if it beats irregularly or if it 'throbs'
  • disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)
  • low blood pressure
  • abnormal muscular body movements or shaking
  • involuntary upward movement of the eyes
  • unusual muscle tone causing distortion of the body
  • fits or convulsions
  • patients may experience "serotonin syndrome" (confusion, sweating, unsteadiness, shaking, diarrhoea) when Zofran is taken in combination with other serotonergic drugs. Serotonergic drugs can include certain types of antidepressants, opioid pain medicines such as tramadol and fentanyl, and lithium. Please note, this is not an exhaustive list. Please discuss with your pharmacist or doctor if you have any concerns
  • severe skin reaction where the top layer of the skin detaches from the lower layers.

If you think you are having an allergic reaction to Zofran Zydis wafers, TELL YOUR DOCTOR IMMEDIATELY or go to the casualty department at your nearest hospital. Symptoms usually include some or all of the following:

  • wheezing
  • swelling of the lips/mouth
  • difficulty in breathing
  • hay fever
  • lumpy rash ("hives")
  • fainting.

This is not a complete list of all possible side effects. Others may occur in some people and there may be some side effects not yet known.

If your nausea (feeling of sickness) or vomiting does not go away, ask your doctor what to do.

In certain illnesses and treatments where Zofran has been used, blood vessel blockage has occurred.

However, it is important to note that blood vessel blockage has also occurred in these illnesses and treatments when Zofran has NOT been used. Discuss this with your doctor if you have any concerns.

Tell your doctor if you notice anything else that is making you feel unwell, even if it is not on this list.

Ask your doctor or pharmacist if you don't understand anything in this list.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

After taking Zofran Zydis wafers

Storage

Keep this medicine where young children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Keep Zofran Zydis wafers in a cool, dry place where it stays below 30°C.

Do not store it, or any other medicine, in a bathroom or near a sink.

Do not leave it in the car or on window sills. Heat and dampness can destroy some medicines.

Keep your Zofran Zydis wafers in their pack until it is time to take them. If taken out of their pack, they may not keep well.

Disposal

If your doctor tells you to stop taking Zofran Zydis wafers, or they have passed their expiry date, ask your pharmacist what to do with any wafers left over.

Product description

What Zofran Zydis wafers look like

Zofran Zydis is a special type of tablet called a 'wafer'.

Zofran Zydis wafers are white, round wafers, with no markings on either side. They come in a foil blister pack of 4 or 10 wafers, which are contained in a box. There is a 4 mg strength and an 8 mg strength.

Ingredients

Zofran Zydis wafers contain either 4 mg or 8 mg of the active ingredient ondansetron. They also contain gelatin, mannitol, aspartame, sodium methyl hydroxybenzoate, sodium propyl hydroxybenzoate and strawberry flavour (The 4 mg wafer may contain up to 0.0015 mg ethanol. The 8 mg wafer may contain up to 0.003 mg ethanol).

Zofran Zydis wafers do not contain gluten or lactose.

Manufacturer

Your Zofran Zydis wafers are supplied by:
Aspen Pharmacare Australia Pty Ltd
34-36 Chandos Street
St Leonards NSW 2065
Australia

Further Information

Pharmaceutical companies are not in a position to give people an individual diagnosis or medical advice. Your doctor or pharmacist is the best person to give you advice on the treatment of your condition. You may also be able to find general information about your disease and its treatment from books, for example in public libraries.

Do not throw this leaflet away. You may need to read it again.

This leaflet was updated in October 2014.

The information provided applies only to: Zofran® Zydis® wafers.

Zofran® is a registered trade mark of Aspen Global Incorporated.

Zydis® is a registered trade mark of RP Scherer Corporation.

Zofran Zydis Wafers 4 mg: AUST R 63054.
Zofran Zydis Wafers 8 mg: AUST R 63055.

©2011 Aspen Global Incorporated.

Published by MIMS April 2015

BRAND INFORMATION

Brand name

Zofran

Active ingredient

Ondansetron

Schedule

S4

 

1 Name of Medicine

Ondansetron hydrochloride dihydrate is the therapeutically active ingredient in Zofran injections, Zofran tablets and Zofran oral liquid.
Ondansetron is the therapeutically active ingredient in Zofran suppositories and in Zofran Zydis wafers.

2 Qualitative and Quantitative Composition

Zofran 4 mg and 8 mg tablets contain 4 and 8 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: lactose monohydrate, microcrystalline cellulose, pregelatinised maize starch, magnesium stearate, hypromellose, titanium dioxide and iron oxide yellow.
Excipients with known effect. Sugars as lactose.
Zofran 24 mg tablets contain 24 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: lactose, microcrystalline cellulose, pregelatinised maize starch, magnesium stearate and Opadry Pink YS-1-14593-A (ARTG PI No: 3522).
Excipients with known effect. Sugars as lactose.
Zofran oral liquid contains 0.8 mg/mL of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: citric acid, sodium citrate dihydrate, sodium benzoate, sorbitol solution (70 percent) (crystallising), purified water and Strawberry Flavouring Liquid SC887891 (ARTG PI No: 140281).
Excipients with known effect. Benzoates and sorbitol (12.6 g per recommended maximum daily dose) which may have a laxative effect or cause diarrhoea.
Zofran Zydis wafers contain 4 and 8 mg of ondansetron and the following excipients: gelatin, mannitol, aspartame, sodium methyl hydroxybenzoate, sodium propyl hydroxybenzoate and Strawberry Flavouring Liquid SC887891 (ARTG PI No: 140281).
Excipients with known effect. Aspartame, hydroxybenzoates and sulphites.
Each 2 mL Zofran injection contains 4 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: citric acid monohydrate, sodium citrate dihydrate, sodium chloride and water for injections.
Each 4 mL Zofran injection contains 8 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: citric acid monohydrate, sodium citrate dihydrate, sodium chloride and water for injections.
Zofran suppositories contain 16 mg of ondansetron and Witepsol (ARTG PI No: 2850).

3 Pharmaceutical Form

Zofran 4 mg tablet. Yellow, oval, bi-convex tablets, engraved with "GXET3" on one face and plain on the other face.
Zofran 8 mg tablet. Yellow, oval, bi-convex tablets, engraved with "GXET5" on one face and plain on the other face.
Zofran oral liquid. A clear, colourless to light yellow liquid.
Zofran Zydis wafer. White, round and plano-convex, no markings on either side.
'Wafer' is used to describe the pharmaceutical dosage form of Zofran Zydis.
Zofran 24 mg tablet*. Pink, oval, bi-convex tablets engraved 'GX CF7' on one face and '24' on the other.
Zofran suppository*. White, smooth homogenous suppository with a torpedo shape.
Zofran injection*. Clear colourless liquid, practically free of particles.
*Not marketed in Australia.

4 Clinical Particulars

4.9 Overdose

Little is at present known about overdosage with ondansetron, however, a limited number of patients received overdoses. Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second degree AV block. In all instances, the events resolved completely. There is no specific antidote for ondansetron, therefore in cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.
Ondansetron prolongs QT interval in a dose dependent fashion. ECG monitoring is recommended in cases of overdose.
Cases consistent with serotonin syndrome have been reported in young children following oral overdose.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Ondansetron did not induce mutations in Salmonella typhimurium, Escherichia coli or Chinese Hamster Ovary cells in the presence or absence of metabolic activation, and showed no potential for causing chromosomal damage in vitro in peripheral human lymphocytes or in vivo in a mouse micronucleus assay. No evidence for DNA damage was observed with ondansetron in a yeast mitotic gene conversion assay.
Carcinogenicity. No evidence for carcinogenic activity was found in two year studies at ondansetron doses up to 10 mg/kg/day by gavage in rats or up to 30 mg/kg/day via drinking water in mice.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSONHYDI.gif CAS number. 99614-01-4 (ondansetron hydrochloride dihydrate); 99614-02-5 (ondansetron).
Description. The chemical name of ondansetron hydrochloride dihydrate is 1,2,3,9-tetrahydro-9- methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl] -4H-carbazol-4-one,hydrochloride dihydrate. The molecular formula of ondansetron hydrochloride dihydrate is C18H19N3O.HCl.2H2O and the relative molecular mass is 365.9. It takes the form of a white to off-white powder with a melting point of 177°C. It is sparingly soluble in water and in alcohol, soluble in methanol and slightly soluble in methylene chloride. It is soluble in saline (0.9% w/v) to about 8 mg/mL. The pKa of ondansetron hydrochloride dihydrate as determined by a solubility procedure is 7.4. The distribution coefficient between n-octanol and water is pH dependent with log D = 2.2 at a pH of 10.6 and log D = 0.6 at a pH of 5.95.
The chemical name of ondansetron is 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H- imidazol-1-yl)methyl] -4H-carbazol-4-one. The molecular formula of ondansetron is C18H19N3O and the relative molecular mass is 293.4. It takes the form of a white to off-white powder with a melting point of approximately 230°C. Ondansetron is practically insoluble in water. Solubility decreases with increasing pH from very slightly soluble at pH 3.5 and pH 5.4 to practically insoluble at pH 8. Ondansetron is soluble in chloroform and slightly soluble in acetonitrile and methanol. The pKa of ondansetron as determined by UV monitored partition method is 7.8. The partition coefficient, log P in n-octanol: water is 2.14.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/ZOFRANST.gif